RE:RE:RE:RE:RE:RE:ZenithG1945V,
I agree top-line Q1 2019 seems likely. Though depending upon how long it takes to hit 250 events and stop dosing, this may stretch top-line into Q2. As I stated before, the duration of the safety follow up period after dosing ends is ambiguous, and whether the 2 month adjudication starts at end of dosing or end of follow up is also ambiguous.
As for full data presentation and publication, I've dwelled on this lately over on Agoracom. One scenario is that they forego top-line data announcement and just go all in at
ACC 2019 in March at the late breaking clinical trial session. Submissions due Dec 5th and accepted presentations listed by end of January for March presentation. This is not unprecedented. Sanofi/Regeneron did this at ACC 2018 for ODYSSEY trial for Praluent/alirocumab.
That may be cutting it close. So more likely top-line announcement will come first followed by full presentation at a
major conference in 2019. There are a few choices for Q2. Vascular Discovery in May. ERA-EDTA in June. American Diabetes in June. They could hit the cardio, renal, diabetes circuit with those trio of conferences, followed by the Alzheimer's AAIC conference in July.
The European Society of Cardiology (ESC) has been one of the big conferences for Resverlogix the past few years. Though the anticipation would be almost unbearable, Resverlogix could wait until Q3 2019 for ESC 2019 to present full data for the first time. And then possibly also present at EASD, ASN, AHA, CTAD through the rest of Q3/Q4 to cover the renal, diabetes and Alzheimer's end of things.
Lots of possibilities and room for speculation!
BDAZ